| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
| ADME/Pharmacokinetics |
Metabolism / Metabolites
2-Hydroxyflutamide is a known metabolite of flutamide in the human body. |
|---|---|
| References |
Ball AL, Kamalian L, Alfirevic A, Lyon JJ, Chadwick AE. Identification of the Additional Mitochondrial Liabilities of 2-Hydroxyflutamide When Compared With its Parent Compound, Flutamide in HepG2 Cells. Toxicol Sci. 2016 Oct;153(2):341-51. doi: 10.1093/toxsci/kfw126.
|
| Additional Infomation |
2-Hydroxyflutamide is a metabolite of flutamide. Flutamide is an oral nonsteroidal anti-androgen drug primarily used to treat prostate cancer. It competes with testosterone and its potent metabolite dihydrotestosterone (DHT) for binding to androgen receptors in the prostate. In this way, it can prevent androgen receptors from stimulating the growth of prostate cancer cells. Due to fewer side effects, flutamide has been superseded by bicalutamide, a newer member of this class of drugs. (Wikipedia)
|
| Molecular Formula |
C11H11F3N2O4
|
|---|---|
| Molecular Weight |
292.21
|
| Exact Mass |
292.067
|
| CAS # |
52806-53-8
|
| Related CAS # |
52806-53-8
|
| PubChem CID |
91649
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
443.8±45.0 °C at 760 mmHg
|
| Melting Point |
125-130℃
|
| Flash Point |
222.2±28.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.546
|
| LogP |
3.16
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
392
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
YPQLFJODEKMJEF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H11F3N2O4/c1-10(2,18)9(17)15-6-3-4-8(16(19)20)7(5-6)11(12,13)14/h3-5,18H,1-2H3,(H,15,17)
|
| Chemical Name |
2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide
|
| Synonyms |
2-HOF 2HOF 2 HOF
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~342.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.56 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.56 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4222 mL | 17.1110 mL | 34.2220 mL | |
| 5 mM | 0.6844 mL | 3.4222 mL | 6.8444 mL | |
| 10 mM | 0.3422 mL | 1.7111 mL | 3.4222 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00913263 | COMPLETEDWITH RESULTS | Drug: 2-hydroxyflutamide (2-HOF) [Liproca Depot] Drug: 2-Hydroxyflutamide |
Prostate Cancer | Lidds AB | 2009-06 | Phase 1 Phase 2 |
| NCT02341404 | COMPLETED | Drug: 2-hydroxyflutamide (2-HOF) | Prostate Cancer | Lidds AB | 2012-05 | Phase 2 |
| NCT03348527 | COMPLETED | Drug: 2-Hydroxyflutamide Depot | Prostate Cancer | Lidds AB | 2017-05-12 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA